A novel strategy for genetic analysis of the p53 tumor suppressor gene is described, based on direct sequencing of the asymmetric polymerase chain reaction (PCR) products. A set of 10 PCR primers was designed which allows to amplify and sequence highly conserved regions of the molecule, i.e. the target areas of p53 mutations. The stepwise optimization of RNA isolation, cDNA synthesis, PCR amplifications and sequencing resulted in a procedure which is faster and more reliable than the techniques used to search for p53 mutations so far. This and similar strategies should be applicable to the study of genetic alterations in antioncogenes or other classes of genes which suffer from subtle mutations potentially scattered along large segments of the molecule.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Establishment of a human ovarian endometrioid carcinoma cell line by constitutive expression of cyclin-dependent kinase 4, cyclin D1 and telomerase reverse transcriptase.
Hum Cell
January 2025
Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193, Japan.
Only a few human ovarian endometrioid carcinoma cell lines are currently available, partly due to the difficulty of establishing cell lines from low-grade cancers. Here, using a cell immortalization strategy consisting of i) inactivation of the p16-pRb pathway by constitutive expression of mutant cyclin-dependent kinase 4 (R24C) (CDK4) and cyclin D1, and ii) acquisition of telomerase reverse transcriptase (TERT) activity, we established a human ovarian endometrioid carcinoma cell line from a 46-year-old Japanese woman. That line, designated JFE-21, has proliferated continuously for over 6 months with a doubling time of ~ 55 h.
View Article and Find Full Text PDFMultiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.
Target Oncol
January 2025
Berenson Cancer Center, West Hollywood, CA, USA.
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with this disease. Key developments include the use of chemotherapy, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
View Article and Find Full Text PDFDecay of self-incompatibility within a lifespan in Physalis acutifolia (Solanaceae).
Plant Reprod
January 2025
Department of Ecology and Evolutionary Biology, University of Colorado, 1900 Pleasant Street, Boulder, CO, 80309, USA.
Self-incompatibility decays with age in plants of Physalis acutifolia, and plants that have transitioned to selfing produce fewer seeds but with comparable viability. Self-compatibility in this system is closely related to flower size, which is in turn dependent on the direction of the cross, suggesting parental effects on both morphology and compatibility. The sharpleaf groundcherry, Physalis acutifolia, is polymorphic for self-compatibility, with naturally occurring self-incompatible (SI) and self-compatible (SC) populations.
View Article and Find Full Text PDFCharacterization of the host specificity of the SH3 cell wall binding domain of the staphylococcal phage 88 endolysin.
Arch Microbiol
January 2025
Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Selangor, 43400, Malaysia.
Bacteriophages produce endolysins at the end of the lytic cycle, which are crucial for lysing the host cells and releasing virion progeny. This lytic feature allows endolysins to act as effective antimicrobial alternatives when applied exogenously. Staphylococcal endolysins typically possess a modular structure with one or two enzymatically active N-terminal domains (EADs) and a C-terminal cell wall binding domain (CBD).
View Article and Find Full Text PDF[Gene editing is changing the treatment of hereditary diseases].
Lakartidningen
January 2025
docent, verksamhetschef, Karolinska centrum för cellterapi (KCC), Karolinska universitetssjukhuset, Stockholm; Karolins-ka ATMP-centrum; institutionen för laboratorie-medicin, Karolinska institutet.
Gene editing is a novel technology within gene therapy, which changes sequences in chromosomal DNA with precision. Even if there are alternative strategies, the Nobel Prize-winning CRISPR/Cas technology has become the dominating principle. During recent years base editing and prime editing, permitting editing without DNA double-strand breaks, have been developed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!